about
ACBD3-mediated recruitment of PI4KB to picornavirus RNA replication sitesCirculation of type 1 vaccine-derived poliovirus in the Philippines in 2001Poliovirus Studies during the Endgame of the Polio Eradication Program.Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity.Development of a reverse transcription-loop-mediated isothermal amplification (RT-LAMP) system for a highly sensitive detection of enterovirus in the stool samples of acute flaccid paralysis cases.Regulation of the yeast Yap1p nuclear export signal is mediated by redox signal-induced reversible disulfide bond formationA Sabin 3-derived poliovirus recombinant contained a sequence homologous with indigenous human enterovirus species C in the viral polymerase coding regionPhosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity.Development of an efficient entire-capsid-coding-region amplification method for direct detection of poliovirus from stool extractsItraconazole inhibits enterovirus replication by targeting the oxysterol-binding proteinDevelopment of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in human serum.An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys.Prolactin Regulatory Element Binding Protein Is Involved in Hepatitis C Virus Replication by Interaction with NS4B.Oxysterol-binding protein family I is the target of minor enviroxime-like compounds.Biochemical characterization of enterovirus 71 3D RNA polymerase.Phosphatidylinositol-4 kinase III beta and oxysterol-binding protein accumulate unesterified cholesterol on poliovirus-induced membrane structure.A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection.Allosteric Regulation of Phosphatidylinositol 4-Kinase III Beta by an Antipicornavirus Compound MDL-860.Quantitative analysis of poliomyelitis-like paralysis in mice induced by a poliovirus replicon.Mechanism of Poliovirus Resistance to Host Phosphatidylinositol-4 Kinase III β Inhibitor.Multiple pathways for establishment of poliovirus infection.Phosphatidylinositol 4-kinase III beta is the target of oxoglaucine and pachypodol (Ro 09-0179) for their anti-poliovirus activities, and is located at upstream of the target step of brefeldin A.[Exploration for anti-enterovirus compounds and analysis on the mechanism of its inhibitory effect on virus infection].Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime.Reply to “Poliovirus-Neutralization Test with Poliovirus Pseudovirus To Measure Neutralizing Antibody in Humans”.Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine.Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine-only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in ChiEssential domains of phosphatidylinositol-4 kinase III β required for enterovirus replicationPoliovirus Evolution toward Independence from the Phosphatidylinositol-4 Kinase III β/Oxysterol-Binding Protein Family I PathwayEvaluation of antigenic differences between wild and Sabin vaccine strains of poliovirus using the pseudovirus neutralization test
P50
Q24298628-CCB3DCED-FA75-40DB-9C36-F3F967E94912Q24559785-3D92968D-6E55-4180-904A-8308806129ACQ30243919-658A1E6F-8065-43FF-9350-564B98C0DFE6Q33370037-82BE40B7-0C8B-4A8A-A02C-BC3B696624E8Q33518940-F9B4C28E-D21B-45FF-A8CC-F7E0FD679D8CQ33969434-2C99CC1E-8D9C-472E-BF89-4FF4D40FF57FQ34045638-B75DC1E6-12E9-4477-8CEF-540B8D48B09CQ34742005-5DD04A2A-2883-43DE-872C-8CAC90B6F1A6Q34917054-506E8EB4-855A-433B-985A-22AF5B74F27EQ35252021-B7C52B98-6FDE-4A1B-9847-1E27B9B3F102Q35530244-76D97E80-36E3-4766-98FE-EBDB2FA4B767Q35948053-9660C462-69F1-4C57-B417-27EFC7A7FDC4Q36736683-F12196E5-AE8B-4A4C-B1AE-F001F6D71A43Q36760237-BD5D7048-E9B6-45D7-9C1A-E69E1FE15177Q38338141-8FD493C1-3BE5-4076-839A-EFA20CDCEA6FQ39023918-3963304E-4742-43F1-9E34-75D2E849314DQ39675700-82A50A4D-E19E-4B4B-BFAA-F215ACC954A8Q40163257-C4A5A14D-E2A5-4911-A29D-8ED841BF80DAQ40222004-3CA7A858-982D-4229-9C71-12682516D05AQ40541292-34B80E76-92D1-4457-9C29-5075779BA5FCQ40925636-64EA9217-652F-47E9-A5A0-7934A6010F49Q41310580-60F9C679-D934-4746-B9A9-403EC7A773E2Q44412527-A2773F57-2BA9-4B2D-AE4B-A973C2B7112FQ46013962-1E0152B9-4AE2-4A98-9378-9C2C00217FD5Q46851128-3D0CEAAB-40BC-4293-81ED-F966CF33B943Q47198460-A014EC09-28E1-4C31-928B-F814081B8B76Q58094255-07F14F28-200E-4544-B96C-8AC1CB596568Q92534399-270B81AB-A087-4299-BA2B-BA12C93A73D5Q92666707-7A2733DB-B91A-4010-895B-375D70887ED5Q92710188-07B36B8E-290B-483A-8BB1-54C5E8334008
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Minetaro Arita
@ast
Minetaro Arita
@en
Minetaro Arita
@es
Minetaro Arita
@nl
type
label
Minetaro Arita
@ast
Minetaro Arita
@en
Minetaro Arita
@es
Minetaro Arita
@nl
prefLabel
Minetaro Arita
@ast
Minetaro Arita
@en
Minetaro Arita
@es
Minetaro Arita
@nl
P106
P1153
56498574300
7202620282
P31
P496
0000-0002-3314-6626